Brain-enriched MicroRNA-184 is downregulated in older adults with major depressive disorder: A translational study

Mendes‐Silva, Ana Paula; Fujimura, Patrícia Tiemi; Silva, Jéssica Regina da Costa; Teixeira, Antônio Lúcio; Vieira, Eliane; Guedes, Pedro H.G.; Barroso, Lucélia Scarabeli Silva; Nicolau, Mariana de Souza; Ferreira, Jéssica Diniz Rodrigues; Bertola, Laiss; Nicolau, Eduardo de Souza; Tolentino-Araújo, Gesiane Thamire; Berlezzi, Camila Moreira Silva Ferreira; Rodrigues, Tamíris Sabrina; Borges, Luiza Diniz Ferreira; Gomes, Matheus de Souza; Amaral, Laurence Rodrigues do; Bonetti, Ana Maria; Ueira-Vieira, Carlos; Diniz, Breno S.

doi:10.1016/j.jpsychires.2019.01.019

Cited by 24 publications

(9 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gheysarzadeh and colleagues observed downregulated serum levels of miR-1202, miR-16-5p, and miR-135a-5p in depressed patients [ 114 ], replicating the results of other studies (for details, see Table 2 ). Decreased plasma levels of miR-184 [ 115 ], let-7g-5p, miR-103a-3p, miR-107, miR-142-3p [ 116 ], and miR-134 [ 117 ] were also observed in depressed patients. Eight weeks of personalized antidepressant treatment was associated with an increase in plasma levels of miR-134 [ 117 ].…”

Section: Mirna Studies Of Depression and Antidepressant Treatments Investigating Blood And Bodymentioning

confidence: 99%

The miRNome of Depression

Żurawek

Turecki

2021

IJMS

View full text Add to dashboard Cite

Depression is an effect of complex interactions between genetic, epigenetic and environmental factors. It is well established that stress responses are associated with multiple modest and often dynamic molecular changes in the homeostatic balance, rather than with a single genetic factor that has a strong phenotypic penetration. As depression is a multifaceted phenotype, it is important to study biochemical pathways that can regulate the overall allostasis of the brain. One such biological system that has the potential to fine-tune a multitude of diverse molecular processes is RNA interference (RNAi). RNAi is an epigenetic process showing a very low level of evolutionary diversity, and relies on the posttranscriptional regulation of gene expression using, in the case of mammals, primarily short (17–23 nucleotides) noncoding RNA transcripts called microRNAs (miRNA). In this review, our objective was to examine, summarize and discuss recent advances in the field of biomedical and clinical research on the role of miRNA-mediated regulation of gene expression in the development of depression. We focused on studies investigating post-mortem brain tissue of individuals with depression, as well as research aiming to elucidate the biomarker potential of miRNAs in depression and antidepressant response.

show abstract

Section: Mirna Studies Of Depression and Antidepressant Treatments Investigating Blood And Bodymentioning

confidence: 99%

The miRNome of Depression

Żurawek

Turecki

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…10 A study of plasma miRNAs identified miR-184 to be associated with late-life depression. 11 A systematic review gleaned plasma miRNAs associated with major depression and AD, respectively, from published studies and identified seven miRNAs common to both disorders. 12 Other studies of brain miRNAs in major depression, though providing valuable information, either focused on candidate miRNAs or had relatively small sample sizes.…”

Section: Introductionmentioning

confidence: 99%

Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia

et al. 2020

View full text Add to dashboard Cite

Late-life depression is associated with an increased risk for dementia but we have limited knowledge of the molecular mechanisms underlying this association. Here we investigated whether brain microRNAs, important posttranscriptional regulators of gene expression, contribute to this association. Late-life depressive symptoms were assessed annually in 300 participants of the Religious Orders Study and Rush Memory and Aging Project for a mean of 7 years. Participants underwent annual cognitive testing, clinical assessment of cognitive status, and uniform neuropathologic examination after death. microRNAs were profiled from the prefrontal cortex using NanoString platform in the discovery cohort and small RNA sequencing in the replication cohort. A global microRNA association study of late-life depressive symptoms was performed using linear mixed model adjusting for the potential confounding factors. Four brain microRNAs were associated with late-life depressive symptoms at adjusted p < 0.05: miR-484, miR-26b-5p, miR-30d-5p, and miR-197-3p. Lower expression levels of these miRNAs were associated having greater depressive symptoms. Furthermore, lower levels of miR-484 and miR-197-3p were associated with faster decline of cognition over time. Moreover, lower miR-484 level was associated with higher probability of having Alzheimer's dementia. Importantly, the associations between miR-484 and depressive symptoms and Alzheimer's dementia, respectively, were replicated in an independent cohort. Lastly, the predicted targets of miR-484 were enriched in a brain protein co-expression module involving synaptic transmission and regulation of synaptic plasticity. This study identified four brain microRNAs associated with late-life depressive symptoms assessed longitudinally. In addition, we found a molecular connection between late-life depression and dementia through miR-484.

show abstract

“…miR-214-3p was significantly upregulated in the medial prefrontal cortex of chronic social defeat stress mice by targeting β-catenin transcripts [80]. Brainenriched miRNA-184 is downregulated in older patients with MD [82]. MD patients had significantly increased exosomal miR-139-5p levels when compared with controls [85].…”

Section: Microrna Biomarkersmentioning

confidence: 96%

MicroRNAs, Multiple Sclerosis, and Depression

Wang

2021

IJMS

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects the brain and spinal cord. There are several disease courses in MS including relapsing–remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). Up to 50% of MS patients experience depressive disorders. Major depression (MD) is a serious comorbidity of MS. Many dysfunctions including neuroinflammation, peripheral inflammation, gut dysbiosis, chronic oxidative and nitrosative stress, and neuroendocrine and mitochondrial abnormalities may contribute to the comorbidity between MS and MD. In addition to these actions, medical treatment and microRNA (miRNA) regulation may also be involved in the mechanisms of the comorbidity between MS and MD. In the study, I review many common miRNA biomarkers for both diseases. These common miRNA biomarkers may help further explore the association between MS and MD.

show abstract

Brain-enriched MicroRNA-184 is downregulated in older adults with major depressive disorder: A translational study

Cited by 24 publications

References 52 publications

The miRNome of Depression

The miRNome of Depression

Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia

MicroRNAs, Multiple Sclerosis, and Depression

Contact Info

Product

Resources

About